Examkin

Question

Difficulty: Very hardBreast Disorders

A 46-year-old woman comes to the clinic to discuss the results of a recent breast biopsy. Two weeks ago, a routine screening mammogram revealed a new, 8-mm cluster of pleomorphic microcalcifications in the upper outer quadrant of her right breast. A stereotactic core needle biopsy was performed. The pathology report indicates atypical ductal hyperplasia and fibrocystic changes containing microcalcifications. The patient has no history of breast disease. Menarche was at age 12, and she is nulliparous. Her mother was diagnosed with breast cancer at age 55. Vital signs are within normal limits. Physical examination reveals symmetrical breasts with no palpable masses, skin changes, nipple discharge, or axillary lymphadenopathy. Which of the following is the most appropriate next step in management?

  1. Needle-localized excisional biopsyAnswer
  2. B
    Repeat screening mammography in 6 months
  3. C
    Initiation of tamoxifen therapy
  4. D
    Unilateral simple mastectomy
  5. E
    Bilateral breast magnetic resonance imaging

Answer

The correct answer is needle-localized excisional biopsy.
The correct answer is needle-localized excisional biopsy. Atypical ductal hyperplasia (ADH) is a high-risk breast lesion. When ADH is diagnosed via stereotactic core needle biopsy, it signifies that the needle sampled a high-risk area, but because the needle only removes a small cylinder of tissue, it cannot evaluate the entire lesion. Studies show that 15% to 30% of lesions diagnosed as ADH on core needle biopsy are upgraded to ductal carcinoma in situ (DCIS) or invasive carcinoma when the entire lesion is surgically excised. Therefore, the standard of care requires a needle-localized excisional biopsy to remove the remaining microcalcifications and definitively rule out malignancy.

Step-by-Step Solution

1
Analyze the patient's presentation and diagnostic findings.
The patient has a stereotactic core needle biopsy of mammographic microcalcifications demonstrating atypical ductal hyperplasia (ADH).
Establishing the specific histological diagnosis is critical for determining the subsequent management algorithm.
2
Determine the clinical significance of the pathology result.
ADH is a high-risk benign lesion. When identified on a core needle biopsy, it carries a 15% to 30% risk of an adjacent, unsampled ductal carcinoma in situ (DCIS) or invasive carcinoma.
Core needle biopsies only sample a small fraction of the targeted lesion, leaving the remainder of the tissue in the breast unexamined.
3
Select the definitive intervention based on the risk of upgrade.
A needle-localized surgical excisional biopsy must be performed to remove the entire area of microcalcifications for complete histological evaluation.
Surgical excision is mandatory to definitively rule out a concurrent malignancy before considering long-term risk reduction strategies like chemoprevention.

Key Concept

Atypical ductal hyperplasia (ADH) diagnosed on core needle biopsy requires subsequent surgical excisional biopsy to rule out concurrent ductal carcinoma in situ (DCIS) or invasive carcinoma.
Rate this question

Topics

Breast Disorders

More questions from this topic